Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates of lymph node in the diagnosis of Diffuse Large B-Cell Lymphoma

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a fast growing and aggressive high grade non-Hodgkin lymphoma (HG-NHL) that spreads quickly, present with lymphadenopathy or enlarged nodes in mediastinum, mesenteric region or peritoneum, from where tissue excision and biopsy with histopathology is not possible. The aim of this study was to diagnose DLBCL by Flow cytometric immunophenotyping (FCI) on fine needle aspirate (FNA) of lymphnode following immunophenotypic diagnostic criteria based on expression of CD markers. All samples were preliminary assessed by fine needle aspiration cytology (FNAC) as NHL or lymph proliferative disorder (LPD). FCI was performed with a complete panel of antibodies (CD3,

Usefulness of Bcl-2 Expression and the Expression of Cytoplasmic Immunoglobulin Light Chains in the Differentiation Between B-Cell Lymphoma and Reactive Lymphocytic Proliferations in FNA

“…In addition, they determined Bcl-2 expression also in 20 various non-Hodgkin lymphomas and in Hodgkin lymphomas, with the maximum number of six cases per lymphoma type. We are aware of only two reports where Bcl-2 expression was investigated on FNA material and results reported in some detail [11,16]. Tarafder et al investigated 10 cases of DLBC lymphomas for a variety of cell markers including Bcl-2 [16], while Laane et al determined Bcl-2 expression on a large number of various samples including 189 BCL and 137 RLP [11].…”

“…Additional differences among the above mentioned papers and our report are also in the use of qualitative or quantitative Bcl-2 determination and in the manner in which Bcl-2 expression was detected. Tarafder et al [16] used only the qualitative method while Cornfield et al [14] and Laane et al [11] used only the quantitative method. Cook et al [15] used both methods as it was presented in our study.…”